172 related articles for article (PubMed ID: 38236605)
21. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
22. Sotorasib for Lung Cancers with
Skoulidis F; Li BT; Dy GK; Price TJ; Falchook GS; Wolf J; Italiano A; Schuler M; Borghaei H; Barlesi F; Kato T; Curioni-Fontecedro A; Sacher A; Spira A; Ramalingam SS; Takahashi T; Besse B; Anderson A; Ang A; Tran Q; Mather O; Henary H; Ngarmchamnanrith G; Friberg G; Velcheti V; Govindan R
N Engl J Med; 2021 Jun; 384(25):2371-2381. PubMed ID: 34096690
[TBL] [Abstract][Full Text] [Related]
23. Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers.
Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura S; Mzannar Y; Azar I; Beal E; Tobon M; Kim S; Beydoun R; Baloglu E; Senapedis W; El-Rayes B; Philip PA; Mohammad RM; Shields AF; Al-Hallak MN; Azmi AS
bioRxiv; 2023 Mar; ():. PubMed ID: 37034616
[TBL] [Abstract][Full Text] [Related]
24. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.
Sabari JK; Velcheti V; Shimizu K; Strickland MR; Heist RS; Singh M; Nayyar N; Giobbie-Hurder A; Digumarthy SR; Gainor JF; Rajan AP; Nieblas-Bedolla E; Burns AC; Hallin J; Olson P; Christensen JG; Kurz SC; Brastianos PK; Wakimoto H
Clin Cancer Res; 2022 Aug; 28(15):3318-3328. PubMed ID: 35404402
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Santos C; Azuara D; Viéitez JM; Páez D; Falcó E; Élez E; López-López C; Valladares M; Robles-Díaz L; García-Alfonso P; Bugés C; Durán G; Salud A; Navarro V; Capellá G; Aranda E; Salazar R
Ann Oncol; 2019 May; 30(5):796-803. PubMed ID: 30840064
[TBL] [Abstract][Full Text] [Related]
26. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.
Kirschner T; Müller MP; Rauh D
J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359
[TBL] [Abstract][Full Text] [Related]
27. Sotorasib's Benefits in Colorectal Cancer Modest.
Cancer Discov; 2022 Mar; 12(3):OF1. PubMed ID: 34987029
[TBL] [Abstract][Full Text] [Related]
28. Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer.
Khawaja H; Briggs R; Latimer CH; Rassel M; Griffin D; Hanson L; Bardelli A; Di Nicolantonio F; McDade SS; Scott CJ; Lambe S; Maurya M; Lindner AU; Prehn JHM; Sousa J; Winnington C; LaBonte MJ; Ross S; Van Schaeybroeck S
Mol Cancer Ther; 2023 Jan; 22(1):135-149. PubMed ID: 36279564
[TBL] [Abstract][Full Text] [Related]
29. Profiling oncogenic KRAS mutant drugs with a cell-based Lumit p-ERK immunoassay.
Swiatnicki M; Engel L; Shrestha R; Alves J; Goueli SA; Zegzouti H
SLAS Discov; 2022 Jun; 27(4):249-257. PubMed ID: 35288294
[TBL] [Abstract][Full Text] [Related]
30. Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer.
Cancer Discov; 2022 Apr; 12(4):878-879. PubMed ID: 35373275
[TBL] [Abstract][Full Text] [Related]
31. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
33. Therapeutics Targeting Mutant KRAS.
Thein KZ; Biter AB; Hong DS
Annu Rev Med; 2021 Jan; 72():349-364. PubMed ID: 33138715
[TBL] [Abstract][Full Text] [Related]
34. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Weiss A; Lorthiois E; Barys L; Beyer KS; Bomio-Confaglia C; Burks H; Chen X; Cui X; de Kanter R; Dharmarajan L; Fedele C; Gerspacher M; Guthy DA; Head V; Jaeger A; Núñez EJ; Kearns JD; Leblanc C; Maira SM; Murphy J; Oakman H; Ostermann N; Ottl J; Rigollier P; Roman D; Schnell C; Sedrani R; Shimizu T; Stringer R; Vaupel A; Voshol H; Wessels P; Widmer T; Wilcken R; Xu K; Zecri F; Farago AF; Cotesta S; Brachmann SM
Cancer Discov; 2022 Jun; 12(6):1500-1517. PubMed ID: 35404998
[TBL] [Abstract][Full Text] [Related]
35. Combating KRASG12C Inhibitor Resistance.
Cancer Discov; 2024 Jan; 14(1):OF3. PubMed ID: 37921413
[TBL] [Abstract][Full Text] [Related]
36. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients.
Taniguchi H; Yamazaki K; Yoshino T; Muro K; Yatabe Y; Watanabe T; Ebi H; Ochiai A; Baba E; Tsuchihara K;
Cancer Sci; 2015 Mar; 106(3):324-7. PubMed ID: 25800101
[TBL] [Abstract][Full Text] [Related]
37. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
38. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
Stratmann JA; Althoff FC; Doebel P; Rauh J; Trummer A; Hünerlitürkoglu AN; Frost N; Yildirim H; Christopoulos P; Burkhard O; Büschenfelde CMZ; Becker von Rose A; Alt J; Aries SP; Webendörfer M; Kaldune S; Uhlenbruch M; Tritchkova G; Waller CF; Rittmeyer A; Hoffknecht P; Braess J; Kopp HG; Grohé C; Schäfer M; Schumann C; Griesinger F; Kuon J; Sebastian M; Reinmuth N
Eur J Cancer; 2024 Apr; 201():113911. PubMed ID: 38377774
[TBL] [Abstract][Full Text] [Related]
39. Sotorasib: First Approval.
Blair HA
Drugs; 2021 Sep; 81(13):1573-1579. PubMed ID: 34357500
[TBL] [Abstract][Full Text] [Related]
40. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
Chen Y; Liu QP; Xie H; Ding J
Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]